How does the U2AF2 recombinant rabbit monoclonal antibody elucidate the splicing pathogenic mechanisms in neurodevelopmental disorders?

I. Why Focus on RNA Splicing Abnormalities in Neurodevelopmental Disorders Research?

Neurodevelopmental disorders are a group of clinically and genetically heterogeneous conditions often characterized by developmental delay, intellectual disability, and may be accompanied by autism spectrum features or epilepsy. De novo mutations are one of the primary pathogenic factors, with over 1,500 associated genes identified to date. Recent studies reveal that precise regulation of precursor messenger RNA splicing is crucial for nervous system development, and its dysregulation is closely linked to various neurodevelopmental disorders. Functional defects in core spliceosome components or splicing regulators can lead to widespread downstream gene expression disturbances, affecting neurogenesis, neuronal differentiation, and neural network formation. Therefore, elucidating the molecular mechanisms of splicing-related gene mutations has become a key breakthrough in understanding the etiology of these disorders. In this research paradigm, highly specific tools such as recombinant rabbit monoclonal antibodies targeting the critical splicing factor U2AF2 provide indispensable technical support for precisely probing its expression, localization, interactions, and functional alterations at the protein level.

II. How Do U2AF2 Mutations Cause Neurodevelopmental Disorders?

The U2AF2 gene encodes a protein that is a key component of the spliceosome, responsible for recognizing polypyrimidine sequences at the 3' end of introns and ensuring correct splice site selection. Recent clinical genetic studies have identified multiple de novo heterozygous U2AF2 mutations in patients with neurodevelopmental disorders. Functional experiments show that some mutant proteins significantly impair their ability to recognize polypyrimidine sequences, leading to reduced splicing efficiency. Biochemical analyses using tools like U2AF2 recombinant rabbit monoclonal antibodies can directly assess mutant protein stability, complex formation capacity, and intracellular distribution changes. In vivo functional studies further confirm that U2AF2 loss-of-function severely impacts brain development, resulting in reduced neural stem cell proliferation and abnormal brain structure. Introducing patient-homologous mutations into human stem cell models, while not affecting cell proliferation, significantly impairs neurite outgrowth in differentiated neurons, suggesting that U2AF2 dysfunction may disrupt neuronal morphogenesis and connectivity, leading to neural network functional defects. These findings collectively establish U2AF2 as a novel causative gene for neurodevelopmental disorders.

III. How to Explore Splicing Regulatory Networks Using U2AF2 Recombinant Rabbit Monoclonal Antibody?

The high specificity and affinity of U2AF2 recombinant rabbit monoclonal antibody make it a powerful tool for in-depth exploration of pathogenic networks in splicing-related neurodevelopmental disorders. Immunoprecipitation coupled with mass spectrometry using this antibody can systematically identify protein complexes interacting with U2AF2, revealing its partner molecules at different spliceosome assembly stages. For example, studies show that mutations in U2AF2 and another core spliceosome protein PRPF19 lead to highly similar clinical phenotypes in patients. Parallel comparative studies using U2AF2 recombinant rabbit monoclonal antibody and PRPF19-specific antibodies help elucidate whether they co-regulate the same set of downstream target gene splicing. Transcriptomic analyses combined with antibody-mediated protein detection reveal that loss-of-function of both U2AF2 and PRPF19 causes aberrant splicing events in a group of neurodevelopment-related genes (e.g., chromatin remodelers ISWI/BRM family members, ribosomal protein genes, RNA-binding protein RBFOX1). This suggests a hierarchical gene expression network regulated by core spliceosome components, whose disruption represents a common pathological basis for neurodevelopmental disorders.

IV. What Is the Role of the Downstream Effector RBFOX1 in Splicing Regulatory Networks?

Further investigation of this splicing regulatory network identified a key downstream node, RBFOX1. RBFOX1 itself is an important tissue-specific splicing regulator whose expression is regulated by upstream spliceosome core components like U2AF2 and PRPF19. RBFOX1 mutations found in patients are located in its RNA-binding domain, impairing its ability to regulate target pre-mRNA splicing. Studying its upstream regulatory mechanisms using tools like U2AF2 recombinant rabbit monoclonal antibody, combined with functional studies of RBFOX1, can construct a more complete pathogenic pathway. For instance, RBFOX1's classic target gene is the neurotrophic factor receptor TrkB, whose impaired splicing directly affects neuronal survival and plasticity. Thus, U2AF2 or PRPF19 mutations may disrupt RBFOX1's normal expression and function, leading to mis-splicing of critical neurodevelopment-related genes like TrkB and ultimately causing disease phenotypes. This reveals a cascade pathogenic mechanism from core spliceosome mutations to tissue-specific splicing regulator dysfunction, and finally to effector gene abnormalities.

V. Which Manufacturers Provide U2AF2 Recombinant Rabbit Monoclonal Antibody?

Hangzhou Start Biotech Co., Ltd. has independently developed the "U2AF2 Recombinant Rabbit Monoclonal Antibody (U2AF2 Recombinant Rabbit mAb (S-1324-1))" (Catalog No.: S0B1060), a high-specificity, high-affinity, and exceptionally stable antibody for detecting core spliceosome factors. This product is developed using the S-RMab® recombinant rabbit monoclonal antibody platform technology, capable of specifically recognizing U2AF2 (U2 small nuclear RNA auxiliary factor 2) protein across multiple species including human, mouse, and rat. It performs excellently in applications such as Western blot (WB), immunofluorescence (IF), immunohistochemistry (IHC), and immunoprecipitation (IP), making it an essential tool for studying RNA splicing regulation, gene expression, tumorigenesis, and developmental biology.

Technical Support: We provide detailed validation data packages for this antibody, including species cross-reactivity validation, application data in various cell lines or tissues, and recommended multi-platform experimental protocols. Our technical team offers professional consultation on RNA biology and disease research applications.

Hangzhou Start Biotech Co., Ltd. is committed to providing high-performance, high-value core research tools for RNA research, oncology, and developmental biology. For more information about the "U2AF2 Recombinant Rabbit Monoclonal Antibody" (Catalog No. S0B1060), to obtain validation data, or to request sample testing, please feel free to contact us.

Product Information

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.